Chicago Equity Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Chicago Equity Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$558K	Sell	13,200 -10,850	-45%	-$447K	0.06%	407
2019 Q4	$1.03M	Sell	24,050 -23,450	-49%	-$1.02M	0.06%	451
2019 Q3	$1.71M	Buy	47,500 +19,505	+70%	+$591K	0.08%	354
2019 Q2	$748K	Buy	+27,995	New	+$715K	0.03%	607
2018 Q1	–	Sell	-7,855	Closed	-$237K	–	747
2017 Q4	$237K	Buy	+7,855	New	+$251K	0.01%	698

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Chicago Equity Partners's ACAD Position: Q1 2020 in Review

Chicago Equity Partners reduced its Acadia Pharmaceuticals (ACAD) stake by 45% in Q1 2020, selling an estimated $447K and leaving 13,200 shares worth $558K. The position accounts for 0.06% of the portfolio, ranked #407.

Chicago Equity Partners first reported a position in ACAD in Q4 2017 and has held it in 5 quarters since. The position peaked at $1.71M in Q3 2019. 245 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

Chicago Equity Partners held 13,200 shares of Acadia Pharmaceuticals worth $558K as of Q1 2020.
Chicago Equity Partners sold 10,850 Acadia Pharmaceuticals shares in Q1 2020, an estimated $447K.
Acadia Pharmaceuticals made up 0.06% of Chicago Equity Partners's portfolio in Q1 2020, its #407 holding.
Chicago Equity Partners first reported a position in Acadia Pharmaceuticals in Q4 2017 and has held it in 5 quarters since.
Chicago Equity Partners's Acadia Pharmaceuticals position peaked at $1.71M in Q3 2019.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.